A high-throughput cell-based gaussia luciferase reporter assay for identifying modulators of fibulin-3 secretion

John D. Hulleman, Steven J. Brown, Hugh Rosen, Jeffery W. Kelly

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

An R345W mutation in fibulin-3 causes its inefficient secretion, increased intracellular steady-state levels, and the macular dystrophy, Malattia Leventinese (ML), a disease similar to age-related macular degeneration. It is unknown whether R345W causes ML through increased intracellular levels, by the secretion of a potentially aggregation-prone protein, or both. To identify small molecules that alter the secretion of fibulin-3, we developed ARPE19 retinal cell lines that inducibly express wild-type (WT) or R345W fibulin-3 fused to an enhanced Gaussia luciferase (eGLuc2). Screening of the Library of Pharmacologically Active Compounds demonstrated that these cell lines and the GLuc assay are suitable for high-throughput chemical screening. Two estrogen-related compounds enhanced fibulin-3 secretion, whereas a diverse series of small molecules reduced fibulin-3 secretion. A counterscreen identified compounds that did not substantially alter the secretion of unfused eGLuc2, demonstrating at least partial selectivity for fibulin-3. A secondary assay using untagged fibulin-3 confirmed that the top three inhibitory compounds reduced R345W fibulin-3 secretion. Interestingly, in untagged fibulin-3 studies, one compound, phorbol 12-myristate 13-acetate, reduced R345W fibulin-3 secretion while minimally enhancing WT fibulin-3 secretion, the desired activity and selectivity we sought for ML. The identified compounds could serve as tools for probing the etiology of fibulin-3-related diseases.

Original languageEnglish (US)
Pages (from-to)647-658
Number of pages12
JournalJournal of Biomolecular Screening
Volume18
Issue number6
DOIs
StatePublished - Jul 2013

Fingerprint

Luciferases
Modulators
Assays
Throughput
Macular Degeneration
fibulin
Screening
Cells
High-Throughput Screening Assays
Cell Line
Molecules
Estrogens
Acetates
Agglomeration
Mutation

Keywords

  • fibulin-3
  • fibulin-3-dependent gliomas
  • Gaussia luciferase
  • high-throughput chemical screening
  • LOPAC
  • Malattia Leventinese

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmacology
  • Biochemistry
  • Molecular Medicine
  • Biotechnology

Cite this

A high-throughput cell-based gaussia luciferase reporter assay for identifying modulators of fibulin-3 secretion. / Hulleman, John D.; Brown, Steven J.; Rosen, Hugh; Kelly, Jeffery W.

In: Journal of Biomolecular Screening, Vol. 18, No. 6, 07.2013, p. 647-658.

Research output: Contribution to journalArticle

@article{b07f6126318141788382b7f468416da9,
title = "A high-throughput cell-based gaussia luciferase reporter assay for identifying modulators of fibulin-3 secretion",
abstract = "An R345W mutation in fibulin-3 causes its inefficient secretion, increased intracellular steady-state levels, and the macular dystrophy, Malattia Leventinese (ML), a disease similar to age-related macular degeneration. It is unknown whether R345W causes ML through increased intracellular levels, by the secretion of a potentially aggregation-prone protein, or both. To identify small molecules that alter the secretion of fibulin-3, we developed ARPE19 retinal cell lines that inducibly express wild-type (WT) or R345W fibulin-3 fused to an enhanced Gaussia luciferase (eGLuc2). Screening of the Library of Pharmacologically Active Compounds demonstrated that these cell lines and the GLuc assay are suitable for high-throughput chemical screening. Two estrogen-related compounds enhanced fibulin-3 secretion, whereas a diverse series of small molecules reduced fibulin-3 secretion. A counterscreen identified compounds that did not substantially alter the secretion of unfused eGLuc2, demonstrating at least partial selectivity for fibulin-3. A secondary assay using untagged fibulin-3 confirmed that the top three inhibitory compounds reduced R345W fibulin-3 secretion. Interestingly, in untagged fibulin-3 studies, one compound, phorbol 12-myristate 13-acetate, reduced R345W fibulin-3 secretion while minimally enhancing WT fibulin-3 secretion, the desired activity and selectivity we sought for ML. The identified compounds could serve as tools for probing the etiology of fibulin-3-related diseases.",
keywords = "fibulin-3, fibulin-3-dependent gliomas, Gaussia luciferase, high-throughput chemical screening, LOPAC, Malattia Leventinese",
author = "Hulleman, {John D.} and Brown, {Steven J.} and Hugh Rosen and Kelly, {Jeffery W.}",
year = "2013",
month = "7",
doi = "10.1177/1087057112469405",
language = "English (US)",
volume = "18",
pages = "647--658",
journal = "Journal of Biomolecular Screening",
issn = "1087-0571",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - A high-throughput cell-based gaussia luciferase reporter assay for identifying modulators of fibulin-3 secretion

AU - Hulleman, John D.

AU - Brown, Steven J.

AU - Rosen, Hugh

AU - Kelly, Jeffery W.

PY - 2013/7

Y1 - 2013/7

N2 - An R345W mutation in fibulin-3 causes its inefficient secretion, increased intracellular steady-state levels, and the macular dystrophy, Malattia Leventinese (ML), a disease similar to age-related macular degeneration. It is unknown whether R345W causes ML through increased intracellular levels, by the secretion of a potentially aggregation-prone protein, or both. To identify small molecules that alter the secretion of fibulin-3, we developed ARPE19 retinal cell lines that inducibly express wild-type (WT) or R345W fibulin-3 fused to an enhanced Gaussia luciferase (eGLuc2). Screening of the Library of Pharmacologically Active Compounds demonstrated that these cell lines and the GLuc assay are suitable for high-throughput chemical screening. Two estrogen-related compounds enhanced fibulin-3 secretion, whereas a diverse series of small molecules reduced fibulin-3 secretion. A counterscreen identified compounds that did not substantially alter the secretion of unfused eGLuc2, demonstrating at least partial selectivity for fibulin-3. A secondary assay using untagged fibulin-3 confirmed that the top three inhibitory compounds reduced R345W fibulin-3 secretion. Interestingly, in untagged fibulin-3 studies, one compound, phorbol 12-myristate 13-acetate, reduced R345W fibulin-3 secretion while minimally enhancing WT fibulin-3 secretion, the desired activity and selectivity we sought for ML. The identified compounds could serve as tools for probing the etiology of fibulin-3-related diseases.

AB - An R345W mutation in fibulin-3 causes its inefficient secretion, increased intracellular steady-state levels, and the macular dystrophy, Malattia Leventinese (ML), a disease similar to age-related macular degeneration. It is unknown whether R345W causes ML through increased intracellular levels, by the secretion of a potentially aggregation-prone protein, or both. To identify small molecules that alter the secretion of fibulin-3, we developed ARPE19 retinal cell lines that inducibly express wild-type (WT) or R345W fibulin-3 fused to an enhanced Gaussia luciferase (eGLuc2). Screening of the Library of Pharmacologically Active Compounds demonstrated that these cell lines and the GLuc assay are suitable for high-throughput chemical screening. Two estrogen-related compounds enhanced fibulin-3 secretion, whereas a diverse series of small molecules reduced fibulin-3 secretion. A counterscreen identified compounds that did not substantially alter the secretion of unfused eGLuc2, demonstrating at least partial selectivity for fibulin-3. A secondary assay using untagged fibulin-3 confirmed that the top three inhibitory compounds reduced R345W fibulin-3 secretion. Interestingly, in untagged fibulin-3 studies, one compound, phorbol 12-myristate 13-acetate, reduced R345W fibulin-3 secretion while minimally enhancing WT fibulin-3 secretion, the desired activity and selectivity we sought for ML. The identified compounds could serve as tools for probing the etiology of fibulin-3-related diseases.

KW - fibulin-3

KW - fibulin-3-dependent gliomas

KW - Gaussia luciferase

KW - high-throughput chemical screening

KW - LOPAC

KW - Malattia Leventinese

UR - http://www.scopus.com/inward/record.url?scp=84879475121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879475121&partnerID=8YFLogxK

U2 - 10.1177/1087057112469405

DO - 10.1177/1087057112469405

M3 - Article

VL - 18

SP - 647

EP - 658

JO - Journal of Biomolecular Screening

JF - Journal of Biomolecular Screening

SN - 1087-0571

IS - 6

ER -